Literature DB >> 19796809

The synergistic effects of lysophosphatidic acid receptor agonists and calcitriol on MG63 osteoblast maturation at titanium and hydroxyapatite surfaces.

Jason P Mansell1, Michele Barbour, Christopher Moore, Maryam Nowghani, Moreica Pabbruwe, Terje Sjostrom, Ashley W Blom.   

Abstract

Successful osseointegration stems from the provision of a mechanically competent mineralised matrix at the implant site. Mature osteoblasts are the cells responsible for achieving this and a key factor for ensuring healthy bone tissue is associated with prosthetic materials will be 1 alpha,25 dihydroxy vitamin D3 (calcitriol). However it is known that calcitriol per se does not promote osteoblast maturation, rather the osteoblasts need to be in receipt of calcitriol in combination with selected growth factors in order to undergo a robust maturation response. Herein we report how agonists of the lysophosphatidic acid (LPA) receptor, LPA and (2S)-OMPT, synergistically co-operate with calcitriol to secure osteoblast maturation for cells grown upon two widely used bone biomaterials, titanium and hydroxyapatite. Efforts could now be focussed on functionalizing these materials with LPA receptor agonists to support in vivo calcitriol-induced osseointegration via heightened osteoblast maturation responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19796809     DOI: 10.1016/j.biomaterials.2009.09.035

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  10 in total

Review 1.  Genetic networks in osseointegration.

Authors:  I Nishimura
Journal:  J Dent Res       Date:  2013-10-24       Impact factor: 6.116

Review 2.  [Research progress on the biological regulatory function of lysophosphatidic acid in bone tissue cells].

Authors:  Xiang-Nan Wu; Yuan-Yuan Ma; Zhi-Chao Hao; Hang Wang
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2020-06-01

3.  Development of a facile fluorophosphonate-functionalised titanium surface for potential orthopaedic applications.

Authors:  Anna I Shiel; Wayne N Ayre; Ashley W Blom; Keith R Hallam; Peter J Heard; Oliver Payton; Loren Picco; Jason P Mansell
Journal:  J Orthop Translat       Date:  2020-07       Impact factor: 5.191

4.  Development and biological evaluation of fluorophosphonate-modified hydroxyapatite for orthopaedic applications.

Authors:  Gráinne Neary; Ashley W Blom; Anna I Shiel; Gabrielle Wheway; Jason P Mansell
Journal:  J Mater Sci Mater Med       Date:  2018-07-21       Impact factor: 3.896

Review 5.  LPA receptor signaling: pharmacology, physiology, and pathophysiology.

Authors:  Yun C Yung; Nicole C Stoddard; Jerold Chun
Journal:  J Lipid Res       Date:  2014-03-18       Impact factor: 5.922

6.  Successful management of repetitive urinary obstruction and anuria caused by double j stent calculi formation after renal transplantation.

Authors:  Zongyao Hao; Li Zhang; Jun Zhou; Xiansheng Zhang; Haoqiang Shi; Yifei Zhang; Pengfei Wei; Chaozhao Liang
Journal:  Case Rep Transplant       Date:  2014-07-06

7.  LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.

Authors:  Kai Sun; Ri-Xin Chen; Jing-Zhang Li; Zhan-Xiong Luo
Journal:  Hereditas       Date:  2022-03-04       Impact factor: 3.271

Review 8.  Autotaxin/Lysophosphatidic Acid Axis: From Bone Biology to Bone Disorders.

Authors:  Candide Alioli; Léa Demesmay; Olivier Peyruchaud; Irma Machuca-Gayet
Journal:  Int J Mol Sci       Date:  2022-03-22       Impact factor: 5.923

9.  Coating of titanium with hydroxyapatite leads to decreased bone formation: A study in rabbits.

Authors:  B G Bøe; R Ø Støen; L B Solberg; F P Reinholt; J E Ellingsen; L Nordsletten
Journal:  Bone Joint Res       Date:  2012-06-01       Impact factor: 5.853

Review 10.  Production of extracellular lysophosphatidic acid in the regulation of adipocyte functions and liver fibrosis.

Authors:  Fang Yang; Guo-Xun Chen
Journal:  World J Gastroenterol       Date:  2018-09-28       Impact factor: 5.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.